Tuesday, October 18, 2016 9:16:57 AM
Proven as One of the Most Effective Digital Tactics Available to Pharmaceutical Manufacturers
ROCHESTER, Mich., Oct. 18, 2016 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (OTCQB:OPRX), a health technology software company whose premier content-delivery platform enables pharmaceutical companies to offer doctors valuable product information and patient support right at point of prescribe, announced independent research results that prove the unique effectiveness and impact of OptimizeRx’s promotional platform for its clients across numerous therapeutic areas.
An image including study results is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a8e5ef08-334a-4cd7-8fd9-6d0ccac665a6
The studies were designed to measure the impact of physicians’ prescribing changes when a copay or free trial was deemed available for a brand named medication that was being considered for ePrescribing. The studies were conducted by Cognizant and Ogilvy Analytics during 2015 and 2016 on behalf of top global pharmaceutical companies who utilized OptimizeRx to deliver their available copay and free trial vouchers with an ePrescription.
The results, along with other independent reviews, confirm that the OptimizeRx platform substantially grows total prescriptions for its promoted brands by delivering meaningful support right at point of care within its network of over 250,000 healthcare providers. In fact, OptimizeRx delivered a return on investment for each pharmaceutical brand that ranged from 300% to 1,200%.
These results are well above the traditional effects of alternate promotional or web advertising results and shows the unique value OptimizeRx’s can deliver to pharmaceutical manufacturers—as well as the highly deemed value this has on doctors who resulted in selecting and prescribing more of the brands who are willing to provide these automated patient savings right within their electronic health records (EHRs).
Doctors now spend over three hours a day using EHRs. As the leading integrator of pharma services within these EHRs, OptimizeRx provides financial and clinical messaging and support directly within the doctor’s prescribing workflow to make it easier for them to offer savings and education to help them start and stay on patients' medications.
“These results clearly show that our services, which are promoted in hundreds of EHR systems, deliver the ROI that pharmaceutical and biotech companies are striving to achieve,” said Terry Hamilton, SVP of Sales of OptimizeRx. “Our clients recognize that they need new ways to reach and support doctors who have less and less time to spend with pharmaceutical sales representatives.”
http://www.globenewswire.com/news-release/2016/10/18/880369/0/en/OptimizeRx-s-Promotional-Programs-Deliver-Return-on-Investment-of-up-to-12-1-ROI.html
Recent OPRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 09:04:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 09:19:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:25:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:24:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:23:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:22:31 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 10:05:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 11:16:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 09:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 10:06:09 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/09/2024 09:28:46 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/05/2024 10:19:24 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/29/2023 10:30:04 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 11/28/2023 09:10:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/13/2023 07:32:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 12:15:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/03/2023 02:49:11 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/30/2023 08:06:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/25/2023 08:00:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 08:31:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/12/2023 06:18:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/06/2023 06:47:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/06/2023 06:47:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/06/2023 06:47:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/06/2023 06:47:06 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM